BioSpace News Archive

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO ® (berotralstat) in Central and Eastern Europe (CEE).

OncXerna Therapeutics, Inc. announced final results from a Phase 2 trial of bavituximab plus pembrolizumab in patients with previously untreated advanced hepatocellular carcinoma and new biomarker data demonstrating that the Xerna™ TME Panel clearly identified trial participants more likely to benefit from treatment.

EyePoint Pharmaceuticals, Inc. today announced that it has entered into a lease agreement to to design and construct a 40,000-square-foot manufacturing facility in Northbridge, Massachusetts to support the global manufacturing of programs, including EYP-1901 and YUTIQ.

Matinas BioPharma today announced that the Company will host a conference call and live audio webcast on Monday, January 30, 2023 at 4:30 p.m. ET to provide a corporate update and discuss the Company’s business outlook for 2023.

Helius Medical Technologies, Inc. today announced preliminary, unaudited results for the quarter and full year ended December 31, 2022.

TScan Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) applications for T-Plex, TSC-204-A0201, and TSC-204-C0702.

Nanoscope Therapeutics Inc. today announced an oral presentation and a poster presentation at the Optogenetics and Optical Manipulation Conference as part of the SPIE Photonics West BiOS Program, taking place January 28-February 2, 2023.

Artemetrx®, the industry’s most preeminent platform for integrated drug cost management, is now even more robust with the launch of its new module, Artemetrx Extend™.

Estar Medical ® has been successful in revoking Regenlab’s original patent for making platelet rich plasma (PRP) at the European Patent Office (EPO).

Compugen Ltd. announced today that Anat Cohen-Dayag , Ph.D., President and CEO, and additional members of its management team will participate in a virtual fireside chat at the upcoming JMP Securities C-Suite Series to discuss Compugen’s leadership in the DNAM-1 axis.